Investing.com – Medtronic (NYSE: MDT) reported second quarter EPS of $1.26, $0.01 better than the analyst estimate of $1.25. Revenue for the quarter came in at $8.4B versus the consensus estimate of $8.28B.
Guidance
Medtronic sees FY 2025 EPS of $5.44-$5.50 versus the analyst consensus of $5.45.
Medtronic’s stock price closed at $87.59. It is down -0.27% in the last 3 months and up 16.54% in the last 12 months.
Medtronic saw 2 positive EPS revisions and 18 negative EPS revisions in the last 90 days. See Medtronic’s stock price’s past reactions to earnings here.
According to InvestingPro, Medtronic’s Financial Health score is “good performance”.
Check out Medtronic’s recent earnings performance, and Medtronic’s financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar